- News & Media
The Supervisory Board of Curetis adds excellent know-how in the in-vitro diagnostics and life science industries and in the venture capital arena and supports Curetis across the entire value chain of its activities.
Detlef Sasse´s career covers more than 30 years as a highly successful professional in the international diagnostics industry, including 20 years in various management positions in the US and Europe. As Vice-President of International Commercial Operations at Beckman Coulter, he was responsible for the markets in Europe, Africa, and the Near and Middle East. His excellent knowledge of the global market, his extensive contacts and his long working experience make Detlef Sasse a true expert on commercialization. Detlef Sasse holds a degree in chemistry.
An engineer by training, Hans-Guenter Hohmann has over 30 years of experience in the life science industry. Since 2004, he has been working as an independent consultant and Board Member of BWcon, a non-profit organization dedicated to promoting business in Baden-Wuerttemberg, Germany. Previously, he was Vice-President and Chairperson of the Executive Board of Agilent Technologies in Germany. Prior to the spin-out of Agilent from Hewlett Packard (HP), he was in charge of HP’s Patient Monitoring Division with facilities in the US and Germany. He also was Managing Director of Hewlett Packard Germany, led HP’s. Analytical Division, which, among others, was developing and commercializing products for the pharmaceutical and biotechnology markets, and has been responsible for R&D in the Medical Group of Hewlett Packard.
Dr. Frank Muehlenbeck is a Partner at aeris CAPITAL, a private investment office advising high-net-worth individuals. At aeris CAPITAL, Dr. Muehlenbeck is responsible for investments in life science companies. He previously worked at Steinbeis, a technology transfer institution in Germany. He studied technical biology at the University of Stuttgart and holds a doctorate in cell biology and immunology.
Dr. Joerg Neermann is a Partner in the Munich Office of LSP Life Sciences Partners. Prior to joining LSP in 2007, he was Managing Partner of DVC Deutsche Venture Capital, where he had been responsible for the overall investment strategy and operations since 2002. He joined DVC in 1998 to develop and build DVC’s life sciences activities. Joerg Neermann started his venture capital career in 1996 at Atlas Venture, where he was a key member of the international life sciences team. He is a member of the Supervisory Board of Affimed Therapeutics (D), Vivendy (CH) and an observer to the Supervisory Board of Probiodrug (D). Dr. Neermann holds an M.S. and a Ph.D. degree in biotechnology from the Technical University of Braunschweig and the Massachusetts Institute of Technology, Cambridge, Mass. He also studied economics at Harvard Business School and at the Technical University of Braunschweig.
Dr. Alexander Asam has 15 years of experience in the life sciences and private equity businesses. Before joining HBM Partners, he was managing director and partner of Deutsche Venture Capital (DVC). Prior to that, he held various positions at Hoechst AG, LION Bioscience AG, Aventis S.A. (now Sanofi-Aventis) and Cache Tektronix Inc.. Alexander Asam received an MBA from ASTON Business School, Birmingham UK, and an MSc and PhD in chemistry from the University of Heidelberg. Has served on numerous boards and is currently also a board member of MIKA Pharma.
Dr. Holger Reithinger is a General Partner and Head of the Munich Office of Forbion. Prior to joining Forbion in 2010, he was Principal and later Partner of Global Life Science Ventures. He started his career in venture capital in 1997 as an Investment Manager at Technologieholding VC GmbH, which was acquired by the 3i Group in early 2000, where Dr. Reithinger became a Director of the German healthcare practice. Dr. Reithinger has served on the Boards of numerous life science companies, including Epigenomics (IPO 2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical, Agendia, and Santaris. Prior to this, Dr. Reithinger gained operational experience as a product development manager at Biometra/WhatmanPlc (now part of GE Healthcare). He holds a PhD in Biochemistry from the University of Frankfurt / Max-Planck-Institute of Biophysics where he worked on protein design in the department of Nobel Laureate Professor Dr. Hartmut Michel.
© Curetis AG 2013